136 related articles for article (PubMed ID: 15177425)
1. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study.
Rigatos SK; Tsavdaridis D; Athanasiadis A; Stathopoulos JG; Stathopoulos GP
Oncol Rep; 2003; 10(6):1817-9. PubMed ID: 14534702
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
6. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
[TBL] [Abstract][Full Text] [Related]
8. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.
Kurtz JE; Rousseau F; Meyer N; Delozier T; Serin D; Nabet M; Djafari L; Dufour P
Oncology; 2007; 73(3-4):210-4. PubMed ID: 18424884
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Rossi D; Baldelli AM; Casadei V; Fedeli SL; Alessandroni P; Catalano V; Giordani P; Ceccolini M; Graziano F; Catalano G
Anticancer Drugs; 2008 Aug; 19(7):733-7. PubMed ID: 18594216
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
15. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin plus paclitaxel in advanced breast cancer.
Dombernowsky P; Boesgaard M; Andersen E; Jensen BV
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
18. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Kreienberg R; Klare P; Kittel K; Sommer H; Heinrich G; Steck T; Lichtenegger W; Elling D; Kümmel S
Cancer Chemother Pharmacol; 2009 Jul; 64(2):401-6. PubMed ID: 19104816
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.
Mlineritsch B; Mayer P; Rass C; Reiter E; Russ G; Vesenmayer G; Oberaigner W; Hausmaninger H
Onkologie; 2004 Oct; 27(5):441-6. PubMed ID: 15585973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
